Evidence map›Paper›PMID 36358871›Full record

ArticleCancers2022

CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3.

Lucas Porras, Faustine Gorse, Ndeye Khady Thiombane, Louis Gaboury, Sylvie Mader

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Multidimensional roles and clinical significance of GATA3 in breast cancer.Frontiers in cell and developmental biology · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lucas PorrasInstitute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3J7, Canada.ORCID 0000-0001-8392-998X
Faustine GorseInstitute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3J7, Canada.ORCID 0000-0001-8859-6192
Ndeye Khady ThiombaneInstitute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3J7, Canada.
Louis GabouryInstitute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3J7, Canada.ORCID 0000-0002-7093-8139
Sylvie MaderInstitute for Research in Immunology and Cancer, Faculty of Medicine, Université de Montréal, Montréal, QC H3C 3J7, Canada.ORCID 0000-0002-6423-627X
Institute for Research in Immunology and Cancer · CAUniversity of British Columbia · CA

Funding

CIHR PJT153178 and PJT156199
6 · The paper itself

Abstract

Estrogen receptor alpha (ERα) expression in ~2/3 breast tumors selects patients for hormonal therapies. Tumors negative for ERα but positive for the progesterone receptor (PR, encoded by

Indexed as

breast cancerCA12/CAXIIER statusERαestrogen signalingGATA3immunostainingluminal tumorsPR

Identifiers

PMID36358871
PMCPMC9657334
OpenAlexW4308721983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.